New ESMO Tumour DNA Scale Helps Match Patients with Cancer to Optimal Targeted Medicines

Tuesday, August 21, 2018 Genetics & Stem Cells News
Email Print This Page Comment bookmark
Font : A-A+

LUGANO, Switzerland, August 21, 2018 /PRNewswire/ --

The ESMO Scale for Clinical Actionability of molecular Targets

 

A new scale for tumour DNA mutations which will simplify and standardise choices for targeted cancer treatment has been agreed by leading cancer specialists in Europe and North

America
. The scale, called ESCAT (ESMO Scale for Clinical Actionability of molecular Targets), is published this week in the Annals of Oncology (1). It aims to optimise patient care by making it easier to identify patients with cancer who are likely to respond to precision medicines, and help make treatment more cost effective.

"Doctors receive a growing amount of information about the genetic make-up of each patient's cancer, but this can be difficult to interpret for making optimal treatment choices," explains Professor Fabrice André, Chair of the ESMO Translational Research and Precision Medicine Working Group who initiated this project. "The new scale will help us distinguish between alterations in tumour DNA that are important for decisions about targeted medicines or access to clinical trials, and those which aren't relevant."

The new grading system classes alterations in tumour DNA according to their relevance as markers for selecting patients for targeted treatment, based on the strength of clinical evidence supporting them (Tier I-V, Table 1). It is the first time that a classification has been developed that is relevant to all potential targeted cancer medicines, not just those that have been approved for use by national regulatory bodies. The classification also enables mutations to be upgraded or downgraded in response to newly available data.

"For the first time, ESMO has created the tools to make it clear what data are needed for a mutation to be considered actionable and how this may change in response to new clinical data," says Dr Joaquin Mateo, lead author of the paper, Principal Investigator of the Prostate Cancer Translational Research Group from the Vall d'Hebron Institute of Oncology, Barcelona, Spain.

"The scale focuses on the clinical evidence for matching tumour mutations with the drugs we have in our clinics and gives us a common vocabulary for communication between clinicians, and for explaining potential treatment benefits to patients," he continues.

As ESMO disseminates ESCAT into clinical practice, it is hoped that cancer centres and laboratories will start to routinely include Tier I-V grading of genomic mutations in patients' clinical and laboratory reports and discuss results at tumour boards and clinics.

"If one mutation is Tier I and another is Tier III, it is important that everyone understands the need to prioritise the Tier I mutation in determining the patient's treatment and implementing precision medicine," Mateo points out.

ESCAT will also make it easier for clinicians and patients to discuss the results of multigene sequencing. More and more patients are offered a multigene sequencing nowadays. Current testing techniques frequently show that many of the genes in a patient's tumour are mutated but it is unclear which are relevant to treatment decisions. By using the scale to show which alterations are relevant, it becomes easier to identify and agree the right treatment for the right patient.

"ESCAT will bring order to the current jungle of mutation analysis so that we all speak the same language for classifying mutations and prioritising how we use them to enhance patient care," concludes André.

Table 1. ESCAT grading system for cancer treatment decision-making 


   
                           Readiness for use in       Current examples of
                           clinical practice          genomic alterations
                                                    


  Tier I (I-A, I-B, I-C)   Targets ready for          HER2 in breast cancer
                           implementation in          BRCA1/2 in ovarian and 
                           routine clinical           breast cancer
                           decisions                  EGFR, ROS1/ALK in NSCLC        
                                                      TRK, PD1 in multiple
                                                      cancers
                                                      BRAF in metastatic
                                                      melanoma
  Tier II (II-A, II-B)     Investigational targets    PTEN pathway (PIK3CA,
                           likely to define           AKT1)
                           patients who benefit
                           from a targeted drug,
                           but additional data
                           needed
                            
  Tier III (III-A, III-B)  Clinical benefit           BRAF in non-melanoma cancers
                           previously demonstrated    PALB2 and other non-BRCA
                           in other tumour type or    DNA repair mutations
                           for similar molecular
                           targets

  Tier IV (IVA, IVB)       Preclinical evidence of    Hypothetical targets for
                           actionability              future clinical testing
                              
  Tier V                   Evidence supporting        PIK3CA in ER+, HER-
                           co-targeting               breast cancer
                           
 
  Tier X                   Lack of evidence
                           for actionability
                       

NSCLC= non-small cell lung cancer

About ESMO 

ESMO is the leading professional organisation for medical oncology. With 18,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information, committed to supporting members to develop and advance in a fast-evolving professional environment. www.esmo.org

Contact: 

ESMO Press Office Vanessa Pavinato +41-91-973-19-07 media@esmo.org

Notes to Editors (1) Mateo J, Chakravarty D, Dienstmann R et al. A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology 2018; https://doi.org/10.1093/annonc/mdy263

SOURCE European Society for Medical Oncology (ESMO)



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store